Ben Creelan, MD MS · @BenCreelan“Is anyone less than impressed w/ #HARMONi ? ▫️PFS at 6.8 mo is less than basic COMPEL trial of chemo + TKI of 8.4 mo. ▫️Looks much like a VEGF curve from the 2000's, not an IO curve. ▫️It requires stopping TKI. For pts w/ prior brain mets, this approach warrants a lot of caution.”
View post ↗See the full HARMONi KOL discussion on KOL Pulse →Updated results from the phase III AEGEAN trial for resectable NSCLC show an event-free survival benefit for perioperative durvalumab plus chemotherapy (EFS HR 0.69), though overall survival is not yet significant (HR 0.89). A new retrospective analysis is also prompting discussion on surgery for early-stage SCLC, which demonstrated a median OS of 88.5 months with surgery vs 26.1 months with chemoradiotherapy in stage I-II disease, though the findings are considered hypothesis-generating.
“With 26m median f/u, EFS favors addition of durvalumab to neoadjuvant chemo (EFS HR 0.69) with OS trend - HR 0.89 but not yet significant (still immature).”
— @StephenVLiu · AEGEAN trial update · View post ↗
“⚠️ Big caveat: retrospective, single-center study with major residual selection bias and substantial stage imbalance. This is hypothesis-generating, not proof that surgery beats CRT.”
— @DrRishabhOnco · SCLC surgery analysis · View post ↗
“🎯Amivantamab discontinuation due to AEs only 7% (vs 34% in MARIPOSA)”
— @HHorinouchi · COPERNICUS trial data · View post ↗📌 Amplified by @KolPulseAI
The comparison of investigational gedatolisib versus alpelisib is a topic of discussion for patients with PIK3CA-mutant metastatic breast cancer. The conversation centers on the potential role for the dual pan-PI3K/mTOR inhibitor gedatolisib in this setting.
“Gedatolisib vs Alpelisib in PIK3CA-Mutant mBC?”
— @breastfriendspd · Gedatolisib vs. Alpelisib · View post ↗📌 Amplified by @KolPulseAI
GI oncologists are discussing the safety nuances of daraxonrasib dosing in practice, and a new review is highlighting how alternative splicing contributes to the clinical heterogeneity of pancreatic cancer (PDAC).
“Asking my smart GI friends what are the nuances of giving the drug safety,”
— @scserendipity1 · Daraxonrasib Toxicity · View post ↗
“🧬Beyond the genome in PDAC: Check our new review exploring how alternative splicing shapes cellular plasticity and clinical heterogeneity in #PDAC”
— @EidMichal · Pancreatic Cancer Biology · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
According to ESMO Clinical Practice Guidelines, the role of prostate radiotherapy (RT) in de novo metastatic castration-sensitive prostate cancer (mCSPC) is guided by disease volume. The STAMPEDE trial demonstrated an overall survival benefit for prostate RT in low-volume disease (OS HR 0.68), while in high-volume disease, the PEACE-1 trial showed RT delays serious GU events and improves CRPC-free survival without a proven OS benefit. Discussion also continues on the practical challenges of implementing ctDNA-guided adjuvant therapy in bladder cancer, including testing frequency and duration.
“Prostate RT in de novo mCSPC: the endpoint depends on volume.”
— @ChandrakanthMv · Prostate RT in mCSPC · View post ↗
“Hypothesis-generating, not a reason to start finasteride for your heart”
— @Adam_Weiner535 · 5-alpha reductase inhibitors · View post ↗“The real challenge may no longer be proving that ctDNA matters. It is knowing how often to test, how long to test, and how confidently we can let ctDNA change treatment.”
— @ChandrakanthMv · ctDNA in Bladder Cancer · View post ↗The FDA approved iberdomide in combination with daratumumab and dexamethasone for relapsed/refractory multiple myeloma (RRMM), with the approval based on improved MRD negativity (41% vs. 21%) rather than a survival endpoint. Additionally, the MAIA trial showed a median overall survival of 90.3 months with daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma. The CANOVA trial, comparing venetoclax-dexamethasone versus pomalidomide-dexamethasone in t(11;14)-positive RRMM, is also a point of discussion.
“(and yes, it was approved on MRD negativity, not PFS!)”
— @khancology · Iberdomide approval endpoint · View post ↗
“@RahulBanerjeeMD on D-Rd achieving mOS of 90.3 months in transplant-ineligible newly diagnosed multiple myeloma (MAIA):”
— @OpenMedKate · MAIA trial overall survival · View post ↗
“#Iberdomide + Dara + Dex in 2L RRMM, improved MRD negativity (41% vs. 21%)”
— @OncBrothers · Iberdomide efficacy data · View post ↗
“Dear my ultimate enemy—extramedullary disease (EMD) in myeloma: Not today.”
— @Abdallah81MD · Extramedullary disease · View post ↗📌 Amplified by @KolPulseAI
The Alliance A051701 trial of DA-EPOCH-R plus venetoclax in double-hit lymphoma is being highlighted as a 'cautionary tale' where increased intensity did not lead to better outcomes. In diagnostics, a study found Whole-Genome Sequencing (WGS) in Myelodysplastic Syndrome uncovers clinically relevant biomarkers missed by standard methods. Discussion also continues on the standard of care for testicular lymphoma, with some asserting that high-dose methotrexate (HD Mtx) remains the standard.
“More is not necessarily better. DA-EPOCH-R + venetoclax in double-hit lymphoma: a cautionary tale from Alliance A051701. More intensity ≠ better outcomes”
— @GomezDLeonMD · Double-Hit Lymphoma · View post ↗
“Whole-Genome Sequencing [WGS] of Pts w/ Myelodysplastic Syndrome Uncovers Novel, Clinically Relevant Biomarkers Missed by Standard-of-Care Methods”
— @mtmdphd · MDS Diagnostics · View post ↗
“In his opinion, HD Mtx remains SoC in testicular lymphoma.”
— @GuiperiniMD · Testicular Lymphoma · View post ↗
“Ask 2 stem cell transplanters about the optimal conditioning and you get 5 answers.”
— @NicoGagelmann · Stem Cell Transplant · View post ↗